touchCONGRESS PARP inhibitors as first-line maintenance therapy in ovarian cancer: Using data from SGO 2022 to inform clinical best practice
Watch this two-part activity exploring recent developments in the use of PARP inhibitors as first-line maintenance therapy in ovarian cancer. Filmed following the SGO Hybrid Annual Meeting on Women’s Cancer 2022.
Part 1: Watch gynaecological cancer expert Prof. Isabelle Ray-Coquard review key data from the SGO Virtual Annual Meeting 2021 Watch Now
Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview
Introduction
Latest efficacy data on PARP inhibitors in the first-line maintenance setting
Latest safety data on PARP inhibitors in the first-line maintenance setting
How could the latest data impact the use of PARP inhibitors in the first-line maintenance treatment of ovarian cancer in clinical practice?
Overview
Watch Prof. Isabelle Ray-Coquard summarize and share her interpretation of the latest data from SGO 2022 on the use of PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer. During the presentation she considers:
- Efficacy data for PARP inhibitors in the first-line maintenance treatment of ovarian cancer
- Safety data for PARP inhibitors in the first-line maintenance treatment of ovarian cancer
- How the latest data may impact the use of PARP inhibitors in the first-lie maintenance treatment of ovarian cancer in clinical practice
Prof. Ray-Coquard is a medical oncologist at the Centre Léon Bérard, University Claude Bernard Lyon I in Lyon, France. read more
Prof. Ray-Coquard obtained her medical degree in 1997 specializing in oncology. In 2003 she received her PhD from the Université Claude Bernard for her research on the independent factors that determine medical practices in oncology. She also received Master’s degrees in statistics in 1995 and in medical economy in 1996.Â
From 2008 to 2013, she served as chair of the gynaecologic group for clinical trials of the French National Cancer Institute (INCA), and she is currently the network director of the national network dedicated to the diagnosis and management of rare gynaecological cancer (www.ovaire-rare.org), a network funded by the INCA commission. At the Groupe d’investigateurs national evaluation des cancers de l’ovaire (GINECO), she has been active in the translational research advisory committee, the scientific committee, and as a chair of the endometrial cancer subgroup and the rare tumours committee. Since 2002, she has also been developing translational research dedicated to ovarian cancer with the INSERM within the CRCL, directed by A Puisieux at the CLB campus, and more directly with research on rare gynaecological cancer biology (e.g. carcinosarcoma, granulosa cell tumours).Â
From 2009 to 2018, Prof. Ray-Coquard was the chair of the rare cancer working group for GCIG (gynaecological cancer intergroup), dedicated to clinical trials in the field of all rare gynaecological cancers. She is the current president of the GINECO group. She is an active member of a number of professional groups, including the American Society of Clinical Oncology, the Connective Tissue Oncology Society, the French Society of Cancer, the European Association of Cancer Research, the EORTC organisation, the European Society of Medical Oncology (ESMO) and the European Society of Gynaecological Oncology (ESGO).
Prof. Isabelle Ray-Coquard discloses: Consulting fees from Amgen, AstraZeneca, Clovis, Deciphera, GlaxoSmithKline, Merck Sharp & Dohme, Mersana and Roche.
Dr Antonio González-MartÃn considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO 2022.
In this interview Dr González-MartÃn answers the following questions:
- How have the clinical trial data regarding first-line maintenance with PARP inhibitors in patients with ovarian cancer changed our understanding of the efficacy of these treatments?
- What have we learned about managing adverse events in patients with ovarian cancer receiving first-line maintenance with PARP inhibitors?
- Based on the presentations at SGO 2022, are you likely to change how you personalize treatment by considering the patient’s molecular characteristics?
- What can we learn from the real-world evidence for first-line maintenance with PARP inhibitors presented at SGO 2022?
- How do you see the role and optimization of PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer evolving in the next 5 years?
Antonio González-MartÃn, MD, PhD, is currently the director of the Cancer Centre Universidad de Navarra in Spain. He is also an associate professor of medicine at Francisco de Vitoria University in Madrid, Spain, where he obtained his PhD. read more
Dr González-MartÃn specializes in the treatment of gynaecological and breast cancer. He is the chair of the Spanish Ovarian Cancer Research Group (GEICO), the GEICO representative in the European Network for Gynecological Oncological Trials (ENGOT), and a representative of GEICO in the Gynecologic Cancer InterGroup (GCIG). He also served as the chair of the ovarian cancer committee in GCIG for the period 2016–2020, and as the chair of ENGOT for the period 2018–2020. In addition, Dr González-MartÃn is a member of the board of the Spanish Society of Medical Oncology (SEOM) and associate editor of the International Journal of Gynecological Cancer.
Dr González-MartÃn has numerous relevant publications in the field of gynaecological and breast cancer.
Dr Antonio González-MartÃn discloses: Consulting/advisory fees from Amgen, AstraZeneca, Clovis, Genab, Mersana and Roche; Speakers’ bureau fees from AstraZeneca, Clovis, GlaxoSmithKline, Merck Sharp & Dohme and Roche; Research funding from GlaxoSmithKline and Roche; and Travel, accommodations or expenses from AstraZeneca, GlaxoSmithKline and Roche.
Dr Sandro Pignata considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO 2022.
In this interview Dr Pignata answers the following questions:
- How have the clinical trial data regarding first-line maintenance with PARP inhibitors in patients with ovarian cancer changed our understanding of the efficacy of these treatments?
- What have we learned about managing adverse events in patients with ovarian cancer receiving first-line maintenance with PARP inhibitors?
- Based on the presentations at SGO 2022, are you likely to change how you personalize treatment by considering the patient’s molecular characteristics?
- What can we learn from the real-world evidence for first-line maintenance with PARP inhibitors presented at SGO 2022?
- How do you see the role and optimization of PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer evolving in the next 5 years?
Dr Sandro Pignata is a medical oncologist and chief of the Division of Medical Oncology of the Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G Pascale in Naples, Italy. read more
Dr Sandro Pignata was born in Naples, Italy. He completed his MD in 1986 at Naples University, and a PhD in gastroenterological science at the University of Rome in 1990. Since 1993 he has been a member of staff at the National Cancer Institute in Naples; he has been the chief of the Division of Medical Oncology of the Department of Urology and Gynecology since 2008.
Dr Pignata is past president of the Multicenter Italian Trial in Ovarian cancer (MITO) group, past chair of the European Network of Gynaecological Oncological Trial Groups (ENGOT), and has been a member of the educational committee of ESMO and the Gynecologic Cancer InterGroup (GCIG).
Dr Sandro Pignata discloses: Honoraria from AstraZeneca, Clovis, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer and Roche; and funding from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer and Roche.
Prof. Isabelle Ray-Coquard considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO 2022.
In this interview Prof. Ray-Coquard answers the following questions:
- How have the clinical trial data regarding first-line maintenance with PARP inhibitors in patients with ovarian cancer changed our understanding of the efficacy of these treatments?
- What have we learned about managing adverse events in patients with ovarian cancer receiving first-line maintenance with PARP inhibitors?
- Based on the presentations at SGO 2022, are you likely to change how you personalize treatment by considering the patient’s molecular characteristics?
- What can we learn from the real-world evidence for first-line maintenance with PARP inhibitors presented at SGO 2022?
- How do you see the role and optimization of PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer evolving in the next 5 years?
Prof. Ray-Coquard is a medical oncologist at the Centre Léon Bérard, University Claude Bernard Lyon I in Lyon, France. read more
Prof. Ray-Coquard obtained her medical degree in 1997 specializing in oncology. In 2003 she received her PhD from the Université Claude Bernard for her research on the independent factors that determine medical practices in oncology. She also received Master’s degrees in statistics in 1995 and in medical economy in 1996.Â
From 2008 to 2013, she served as chair of the gynaecologic group for clinical trials of the French National Cancer Institute (INCA), and she is currently the network director of the national network dedicated to the diagnosis and management of rare gynaecological cancer (www.ovaire-rare.org), a network funded by the INCA commission. At the Groupe d’investigateurs national evaluation des cancers de l’ovaire (GINECO), she has been active in the translational research advisory committee, the scientific committee, and as a chair of the endometrial cancer subgroup and the rare tumours committee. Since 2002, she has also been developing translational research dedicated to ovarian cancer with the INSERM within the CRCL, directed by A Puisieux at the CLB campus, and more directly with research on rare gynaecological cancer biology (e.g. carcinosarcoma, granulosa cell tumours).Â
From 2009 to 2018, Prof. Ray-Coquard was the chair of the rare cancer working group for GCIG (gynaecological cancer intergroup), dedicated to clinical trials in the field of all rare gynaecological cancers. She is the current president of the GINECO group. She is an active member of a number of professional groups, including the American Society of Clinical Oncology, the Connective Tissue Oncology Society, the French Society of Cancer, the European Association of Cancer Research, the EORTC organisation, the European Society of Medical Oncology (ESMO) and the European Society of Gynaecological Oncology (ESGO).
Prof. Isabelle Ray-Coquard discloses: Consulting fees from Amgen, AstraZeneca, Clovis, Deciphera, GlaxoSmithKline, Merck Sharp & Dohme, Mersana and Roche.
Please Select A Video:
Overview & Learning Objectives
Overview
Get an update on the use of PARP inhibitors as first-line maintenance treatment for ovarian cancer in this two-part activity. Filmed following the SGO Hybrid Annual Meeting on Women’s Cancer 2022.
Learning Objectives
- Describe efficacy data for PARP inhibitors in the first-line maintenance treatment of ovarian cancer
- Recall the safety data for PARP inhibitors in the first-line maintenance treatment of ovarian cancer
- Evaluate how the latest data may impact the use of PARP inhibitors as first-line maintenance therapy in clinical practice
Register to touchONCOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
